Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVE: I. Determine the overall response rate of ixazomib in participants with Kaposi sarcoma. SECONDARY OBJECTIVES: I. Determine safety and tolerability of ixazomib. II. Assess changes in Kaposi-sarcoma associated herpesvirus (KSHV) viral load (VL) by ixazomib. III. Correlate changes in KSHV VL with tumor response. IV. For human immunodeficiency virus (HIV)-positive participants, assess changes in CD4 counts and HIV viral load. EXPLORATORY OBJECTIVE: I. Assess changes in quality of life during ixazomib therapy. OUTLINE: Patients receive ixazomib orally (PO) on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks, then periodically for up to 2 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04305691
Study type Interventional
Source AIDS Malignancy Consortium
Contact
Status Recruiting
Phase Phase 2
Start date November 7, 2023
Completion date May 30, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06445166 - Propranolol for the Treatment of Kaposi Sarcoma in Adults Phase 2
Recruiting NCT04941274 - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma Phase 1/Phase 2
Completed NCT03160183 - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting NCT03993106 - A Study of sEphB4-HSA in Kaposi Sarcoma Phase 2
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Completed NCT00395278 - Development of Serologic Assays for Human Herpes Virus-8
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT03296553 - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. Phase 2
Completed NCT03316274 - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma Early Phase 1
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Terminated NCT04893018 - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Phase 1
Recruiting NCT06375122 - Natural History Study of Kaposi Sarcoma
Recruiting NCT05663502 - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Recruiting NCT05329792 - L19IL2/L19TNF in Skin Cancer Patients Phase 2
Not yet recruiting NCT05411237 - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Phase 3
Completed NCT03050788 - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma N/A
Completed NCT03404297 - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya N/A
Terminated NCT01412515 - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma Phase 2
Not yet recruiting NCT06004011 - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) N/A
Withdrawn NCT02229981 - Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma Phase 1/Phase 2